USD 1.49
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| CUE | 7.2 | 12.0 | 38.0 | 0.7 | 122.4 | -43.6 | -85.9 | -90.4 | -87.2 | -87.2 |
| S&P 500 | -0.3 | 1.4 | 1.1 | 5.0 | 11.8 | 24.7 | 40.3 | 88.1 | 196.6 | 34448.4 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | CUE |
| name | Cue Biopharma, Inc. |
| price | 1.49 |
| changes percentage | 7.1942 |
| change | 0.1 |
| day low | 1.36 |
| day high | 1.49 |
| year high | 2.82 |
| year low | 0.45 |
| market cap | 94391947 |
| price avg 50 | 1.2159 |
| price avg 200 | 1.20048 |
| exchange | NASDAQ |
| volume | 387595 |
| avg volume | 500973 |
| open | 1.4 |
| previous close | 1.39 |
| eps | -0.91 |
| pe | -1.64 |
| earnings announcement | 2025-03-26T20:00:00.000+0000 |
| shares outstanding | 63350300 |
| timestamp | 2025-01-24 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001645460 | |||
| revenue | 5490000 | 1245227 | 340.88 |
| gross profit | -32607000 | -560828 | -5714.08 |
| gross profit ratio | -5.94 | -0.45 | -1218.73 |
| research and development expenses | 40802000 | 38578083 | 5.76 |
| operating expenses | 19542000 | 54746669 | -64.30 |
| interest income | 2661000 | 928242 | 186.67 |
| interest expense | 1245000 | 713815 | 74.41 |
| ebitda | -46052000 | -50490510 | 8.79 |
| ebitdaratio | -8.39 | -40.77 | 79.42 |
| operating income | -52149000 | -53224809 | 2.02 |
| operating income ratio | -9.5 | -42.74 | 77.78 |
| net income | -50733000 | -52795955 | 3.91 |
| net income ratio | -9.24 | -42.4 | 78.20 |
| eps | -1.11 | -1.48 | 25.00 |
Revenue Growth: revenue increased to 5 million in 2023 from 1 million in 2022 representing a change of 340.88%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 41 million in 2023 from 39 million in 2022 representing a change of 5.76%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 20 million in 2023 from 55 million in 2022 representing a change of -64.3%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -1.11 in 2023 from -1.11 in 2022 representing a change of 25.0%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -33 million in 2023 from -1 million in 2022 representing a change of -5714.08%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -46 million in 2023 from -50 million in 2022 representing a change of 8.79%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -52 million in 2023 from -53 million in 2022 representing a change of 2.02%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -51 million in 2023 from -53 million in 2022 representing a change of 3.91%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001645460 | |||
| revenue | 3336000 | 2658000 | 25.51 |
| gross profit | 3336000 | -6872000 | 148.54 |
| gross profit ratio | 1 | -2.59 | 138.68 |
| research and development expenses | 9381000 | 9530000 | -1.56 |
| operating expenses | 12151000 | 13041000 | -6.82 |
| interest income | 343000 | 427000 | -19.67 |
| interest expense | 188000 | 215000 | -12.56 |
| ebitda | -7593000 | -9090000 | 16.47 |
| ebitdaratio | -2.28 | -3.42 | 33.45 |
| operating income | -8815000 | -10383000 | 15.10 |
| operating income ratio | -2.64 | -3.91 | 32.36 |
| net income | -8660000 | -10171000 | 14.86 |
| net income ratio | -2.6 | -3.83 | 32.16 |
| eps | -0.17 | -0.2 | 15.00 |
Revenue Growth: revenue increased to 3 million in 2024Q3 from 3 million in 2024Q2 representing a change of 25.51%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 3 million in 2024Q3 from -7 million in 2024Q2 representing a change of 148.54%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 12 million in 2024Q3 from 13 million in 2024Q2 representing a change of -6.82%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Operating Income: Operating income increased to -9 million in 2024Q3 from -10 million in 2024Q2 representing a change of 15.1%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -9 million in 2024Q3 from -10 million in 2024Q2 representing a change of 14.86%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.17 in 2024Q3 from -0.17 in 2024Q2 representing a change of 15.0%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 9 million in 2024Q3 from 10 million in 2024Q2 representing a change of -1.56%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -8 million in 2024Q3 from -9 million in 2024Q2 representing a change of 16.47%. The decrease in EBITDA indicates declined operational efficiency and profitability.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001645460 | |||
| total assets | 61530000 | 91283452 | -32.59 |
| total liabilities | 24445000 | 25600877 | -4.51 |
| total equity | 37085000 | 65682575 | -43.54 |
| cash and cash equivalents | 48514000 | 51614102 | -6.01 |
| short term investments | 0 | 24674903 | -100.00 |
| long term investments | 151000 | 150000 | 0.67 |
| total current assets | 51454000 | 77187474 | -33.34 |
| total non current assets | 10076000 | 14095978 | -28.52 |
| total current liabilities | 17081000 | 11548535 | 47.91 |
| total non current liabilities | 7364000 | 14052342 | -47.60 |
| common stock | 47000 | 43042 | 9.20 |
| retained earnings | -301190000 | -250456596 | -20.26 |
| total debt | 14695000 | 19315543 | -23.92 |
Total Assets: Total Assets decreased to 62 million in 2023 from 91 million in 2022 representing a change of -32.59%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 37 million in 2023 from 66 million in 2022 representing a change of -43.54%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 49 million in 2023 from 52 million in 2022 representing a change of -6.01%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2023 from 25 million in 2022 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 51 million in 2023 from 77 million in 2022 representing a change of -33.34%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 17 million in 2023 from 12 million in 2022 representing a change of 47.91%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -301 million in 2023 from -250 million in 2022 representing a change of -20.26%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 24 million in 2023 from 26 million in 2022 representing a change of -4.51%. This indicates a decrease in overall liabilities.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 9.2%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 15 million in 2023 from 19 million in 2022 representing a change of -23.92%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001645460 | |||
| total assets | 44810000 | 42329000 | 5.86 |
| total liabilities | 19444000 | 20707000 | -6.10 |
| total equity | 25366000 | 21622000 | 17.32 |
| cash and cash equivalents | 32420000 | 30029000 | 7.96 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 37256000 | 33900000 | 9.90 |
| total non current assets | 7554000 | 8429000 | -10.38 |
| total current liabilities | 16790000 | 16459000 | 2.01 |
| total non current liabilities | 2654000 | 4248000 | -37.52 |
| common stock | 60000 | 48000 | 25.00 |
| retained earnings | -332368000 | -323708000 | -2.68 |
| total debt | 9512000 | 11263000 | -15.55 |
Total Assets: Total Assets increased to 45 million in 2024Q3 from 42 million in 2024Q2 representing a change of 5.86%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 19 million in 2024Q3 from 21 million in 2024Q2 representing a change of -6.1%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 25 million in 2024Q3 from 22 million in 2024Q2 representing a change of 17.32%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 32 million in 2024Q3 from 30 million in 2024Q2 representing a change of 7.96%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 37 million in 2024Q3 from 34 million in 2024Q2 representing a change of 9.9%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 25.0%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 10 million in 2024Q3 from 11 million in 2024Q2 representing a change of -15.55%. This indicates a reduction in overall debt burden.
Total Current Liabilities: Total Current Liabilities increased to 17 million in 2024Q3 from 16 million in 2024Q2 representing a change of 2.01%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -332 million in 2024Q3 from -324 million in 2024Q2 representing a change of -2.68%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001645460 | |||
| net change in cash | -3099000 | -12756698 | 75.71 |
| operating cash flow | -39961000 | -41805954 | 4.41 |
| free cash flow | -39961000 | -41976700 | 4.80 |
| capital expenditure | 0 | -170746 | 100.00 |
| depreciation and amortization | 3436000 | 1806055 | 90.25 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 8180000 | 9496000 | -13.86 |
| accounts payables | 770000 | 83110 | 826.48 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 6205 | -100.00 |
| investments in property plant and equipment | 0 | -170746 | 100.00 |
| net cash used for investing activites | 25002000 | -24609877 | 201.59 |
| debt repayment | -2000000 | 10000000 | -120.00 |
| common stock issued | 13387000 | 39300000 | -65.94 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 11860000 | 53659000 | -77.90 |
| cash at end of period | 48665000 | 51764102 | -5.99 |
| accounts receivables | -1641000 | 3085275 | -153.19 |
| cash at beginning of period | 51764000 | 64520800 | -19.77 |
Net Change in Cash: Net Change in Cash increased to -3 million in 2023 from -13 million in 2022 representing a change of 75.71%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -40 million in 2023 from -42 million in 2022 representing a change of 4.41%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -40 million in 2023 from -42 million in 2022 representing a change of 4.8%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 8 million in 2023 from 9 million in 2022 representing a change of -13.86%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -2 million in 2023 from 3 million in 2022 representing a change of -153.19%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from 0 million in 2022 representing a change of 100.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2023 from 0 million in 2022 representing a change of 826.48%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001645460 | |||
| operating cash flow | -7527000 | -9990000 | 24.65 |
| free cash flow | -7526000 | -10000000 | 24.74 |
| capital expenditure | 1000 | -10000 | 110.00 |
| depreciation and amortization | 877000 | 862000 | 1.74 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 1583000 | 1755000 | -9.80 |
| accounts receivables | -1305000 | -447000 | -191.95 |
| accounts payables | 2567000 | -13000 | 19846.15 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 1000 | -10000 | 110.00 |
| net cash used for investing activites | 98000 | -10000 | 1080.00 |
| debt repayment | -1000000 | -1000000 | 0.00 |
| common stock issued | 10821000 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 9821000 | -1000000 | 1082.10 |
| net change in cash | 2543000 | -11000000 | 123.12 |
| cash at end of period | 32572000 | 30029000 | 8.47 |
| cash at beginning of period | 30029000 | 41029000 | -26.81 |
Net Change in Cash: Net Change in Cash increased to 3 million in 2024Q3 from -11 million in 2024Q2 representing a change of 123.12%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -8 million in 2024Q3 from -10 million in 2024Q2 representing a change of 24.65%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -8 million in 2024Q3 from -10 million in 2024Q2 representing a change of 24.74%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 2 million in 2024Q3 from 2 million in 2024Q2 representing a change of -9.8%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Receivables: Accounts Receivables decreased to -1 million in 2024Q3 from 0 million in 2024Q2 representing a change of -191.95%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 110.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 3 million in 2024Q3 from 0 million in 2024Q2 representing a change of 19846.15%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q2 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.12 | 0.03 | 243.51 |
| net income per share | -1.11 | -1.48 | 25.13 |
| operating cash flow per share | -0.87 | -1.17 | 25.52 |
| free cash flow per share | -0.87 | -1.18 | 25.83 |
| cash per share | 1.06 | 2.14 | -50.45 |
| book value per share | 0.81 | 1.84 | -56.01 |
| tangible book value per share | 0.81 | 1.84 | -56.01 |
| shareholders equity per share | 0.81 | 1.84 | -56.01 |
| interest debt per share | 0.35 | 0.56 | -37.99 |
| market cap | 120792656.16 | 101600031.9 | 18.89 |
| enterprise value | 86973656.16 | 69301472.9 | 25.50 |
| pe ratio | -2.38 | -1.92 | -23.72 |
| price to sales ratio | 22.0 | 81.59 | -73.03 |
| pocfratio | -3.02 | -2.43 | -24.38 |
| pfcf ratio | -3.02 | -2.42 | -24.89 |
| pb ratio | 3.26 | 1.55 | 110.57 |
| ptb ratio | 3.26 | 1.55 | 110.57 |
| ev to sales | 15.84 | 55.65 | -71.53 |
| enterprise value over ebitda | -1.89 | -1.37 | -37.60 |
| ev to operating cash flow | -2.18 | -1.66 | -31.29 |
| ev to free cash flow | -2.18 | -1.65 | -31.83 |
| earnings yield | -0.42 | -0.52 | 19.18 |
| free cash flow yield | -0.33 | -0.41 | 19.93 |
| debt to equity | 0.4 | 0.29 | 34.75 |
| debt to assets | 0.24 | 0.21 | 12.87 |
| net debt to ebitda | 0.73 | 0.64 | 14.80 |
| current ratio | 3.01 | 6.68 | -54.93 |
| interest coverage | -41.89 | -74.56 | 43.82 |
| income quality | 0.79 | 0.79 | -0.12 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 3.04 | 12.98 | -76.60 |
| research and ddevelopement to revenue | 7.43 | 30.98 | -76.01 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | -0.0 | 100.00 |
| capex to revenue | 0 | 0.14 | -100.00 |
| capex to depreciation | 0 | 0.09 | -100.00 |
| stock based compensation to revenue | 1.49 | 7.63 | -80.46 |
| graham number | 4.5 | 7.84 | -42.61 |
| roic | -1.01 | -0.62 | -61.49 |
| return on tangible assets | -0.82 | -0.58 | -42.56 |
| graham net net | 0.55 | 1.42 | -61.08 |
| working capital | 34373000 | 65638939 | -47.63 |
| tangible asset value | 37085000 | 65682575 | -43.54 |
| net current asset value | 27009000 | 51586597 | -47.64 |
| invested capital | 41491000 | 76340872 | -45.65 |
| average receivables | 877626 | 1599889.5 | -45.14 |
| average payables | 3116000 | 2660850.5 | 17.11 |
| average inventory | 0.5 | 1 | -50.00 |
| days sales outstanding | 112.89 | 16.78 | 572.70 |
| days payables outstanding | 33.54 | 551.93 | -93.92 |
| days of inventory on hand | 0 | 0.0 | -100.00 |
| receivables turnover | 3.23 | 21.75 | -85.13 |
| payables turnover | 10.88 | 0.66 | 1545.47 |
| inventory turnover | 0 | 1806055 | -100.00 |
| roe | -1.37 | -0.8 | -70.19 |
| capex per share | 0 | 0.0 | -100.00 |
ROE: Return on Equity (ROE) decreased to -1.37 on 2023-12-31 from -0.80 on 2022-12-31, representing a change of -70.19%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.38 on 2023-12-31 from -1.92 on 2022-12-31, representing a change of -23.72%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 3.01 on 2023-12-31 from 6.68 on 2022-12-31, representing a change of -54.93%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.40 on 2023-12-31 from 0.29 on 2022-12-31, representing a change of 34.75%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| CUE | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.07 | 0.05 | 22.92 |
| net income per share | -0.17 | -0.2 | 16.61 |
| operating cash flow per share | -0.15 | -0.2 | 26.21 |
| free cash flow per share | -0.15 | -0.2 | 26.29 |
| cash per share | 0.63 | 0.6 | 5.74 |
| book value per share | 0.5 | 0.43 | 14.90 |
| tangible book value per share | 0.5 | 0.43 | 14.90 |
| shareholders equity per share | 0.5 | 0.43 | 14.90 |
| interest debt per share | 0.19 | 0.23 | -17.23 |
| market cap | 38791129.6 | 51178251.12 | -24.20 |
| enterprise value | 15883129.6 | 32412251.12 | -51.00 |
| pe ratio | -1.12 | -1.26 | 10.98 |
| price to sales ratio | 11.63 | 19.25 | -39.61 |
| pocfratio | -5.15 | -5.12 | -0.60 |
| pfcf ratio | -5.15 | -5.12 | -0.71 |
| pb ratio | 1.53 | 2.37 | -35.39 |
| ptb ratio | 1.53 | 2.37 | -35.39 |
| ev to sales | 4.76 | 12.19 | -60.96 |
| enterprise value over ebitda | -2.09 | -3.57 | 41.34 |
| ev to operating cash flow | -2.11 | -3.24 | 34.96 |
| ev to free cash flow | -2.11 | -3.24 | 34.89 |
| earnings yield | -0.22 | -0.2 | -12.33 |
| free cash flow yield | -0.19 | -0.2 | 0.71 |
| debt to equity | 0.37 | 0.52 | -28.01 |
| debt to assets | 0.21 | 0.27 | -20.22 |
| net debt to ebitda | 3.02 | 2.06 | 46.14 |
| current ratio | 2.22 | 2.06 | 7.73 |
| interest coverage | -46.89 | -48.29 | 2.91 |
| income quality | 0.87 | 0.98 | -11.51 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.86 | 1.32 | -34.94 |
| research and ddevelopement to revenue | 2.81 | 3.59 | -21.57 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | 86.73 |
| capex to revenue | 0.0 | 0.0 | -92.03 |
| capex to depreciation | 0.0 | 0.01 | -90.17 |
| stock based compensation to revenue | 0.47 | 0.66 | -28.13 |
| graham number | 1.37 | 1.4 | -2.11 |
| roic | -0.25 | -0.29 | 12.52 |
| return on tangible assets | -0.19 | -0.24 | 19.57 |
| graham net net | 0.3 | 0.21 | 40.32 |
| working capital | 20466000 | 17441000 | 17.34 |
| tangible asset value | 25366000 | 21622000 | 17.32 |
| net current asset value | 17812000 | 13193000 | 35.01 |
| invested capital | 25070000 | 22918000 | 9.39 |
| average receivables | 2499500 | 1623500 | 53.96 |
| average payables | 5190000 | 3912500 | 32.65 |
| average inventory | 0 | 0.5 | -100.00 |
| days sales outstanding | 85.04 | 62.54 | 35.97 |
| days payables outstanding | 0 | 36.89 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 1.06 | 1.44 | -26.46 |
| payables turnover | 0 | 2.44 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.34 | -0.47 | 27.42 |
| capex per share | 0.0 | 0.0 | -90.21 |
ROE: Return on Equity (ROE) increased to -0.34 on 2024-09-30 Q3 from -0.47 on 2024-06-30 Q2, representing a change of 27.42%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.12 on 2024-09-30 Q3 from -1.26 on 2024-06-30 Q2, representing a change of 10.98%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.22 on 2024-09-30 Q3 from 2.06 on 2024-06-30 Q2, representing a change of 7.73%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.37 on 2024-09-30 Q3 from 0.52 on 2024-06-30 Q2, representing a change of -28.01%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-29 16:30:00
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Company as inducement material to Dr. Baker entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (“the Inducement Award”).
Sentiment: Negative
Publish Date: 2024-11-25 08:00:00
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
Sentiment: Negative
Publish Date: 2024-11-14 18:25:14
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.24 per share a year ago.
Sentiment: Negative
Publish Date: 2024-11-14 16:05:00
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024.
Sentiment: Positive
Publish Date: 2024-11-14 08:00:00
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that Daniel Baker, M.D., will join Cue Biopharma as interim chief development officer (CDO) effective November 25, 2024. Dr. Anish Suri will transition from his current role of president & chief scientific officer (CSO) and will serve the company as principal research and immunology advisor effective as of the same date.
Sentiment: Positive
Publish Date: 2024-11-08 13:30:00
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today presented updated data from its Phase 1 dose escalation and expansion trial evaluating its lead oncology asset from the Immuno-STAT™ CUE-100 series, CUE-101, in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data was presented in an oral session at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) being held in Houston, Texas and virtually November 6-10.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
